-
公开(公告)号：USD783525S1
公开(公告)日：2017-04-11
申请号：US29544013
申请日：2015-10-29
-
公开(公告)号：USD756910S1
公开(公告)日：2016-05-24
申请号：US29512597
申请日：2014-12-19
-
公开(公告)号：US08393371B2
公开(公告)日：2013-03-12
申请号：US12754982
申请日：2010-04-06
IPC分类号： B32B37/10
CPC分类号： B29C70/342
摘要： A system for processing a composite material may comprise a chamber, a mandrel, an upper ramp, and an upper diaphragm. The chamber generally provides structural support while a vacuum is applied to the system and may have a six-sided generally rectangular box shape. The mandrel generally provides support for the composite material, and may be located within the chamber. The upper ramp generally provides a path for the upper diaphragm to follow under vacuum, and may be located adjacent to the mandrel and tilted at approximately 45 degrees downward thereto. The upper diaphragm may be placed over an opening along one side of the chamber. During processing, a vacuum may be applied to chamber and the upper diaphragm may be pulled inward through the opening to press the composite material against the mandrel.
摘要翻译： 用于处理复合材料的系统可以包括腔室，心轴，上斜面和上隔膜。 腔室通常提供结构支撑，同时将真空施加到系统上，并且可具有六面体大致矩形的箱形。 心轴通常为复合材料提供支撑，并且可以位于腔室内。 上斜面通常提供用于上隔膜在真空下跟随的路径，并且可以位于与心轴相邻并且向下倾斜约45度的位置。 上隔膜可以放置在沿腔室一侧的开口上。 在处理过程中，真空可以施加到室，并且上隔膜可以通过开口向内拉，以将复合材料压靠在心轴上。
-
4.发明授权Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) 有权衍生自命名为雌激素（MA）的新型早期妊娠因子的生物活性多肽公开(公告)号：US07994278B1
公开(公告)日：2011-08-09
申请号：US09632831
申请日：2000-08-04
CPC分类号： C07K16/26 , A61K38/00 , A61K48/00 , C07K14/59 , C07K2319/00
摘要： The invention relates to therapeutic polypeptides isolated from beta-human chorionic gonadotropin (β-hCG) found in human early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, prohematopoietic (e.g., anemias, radiation-mediated bone marrow damage, and trauma-mediated blood loss), and anti-angiogenic effects. The invention also provides pharmaceutical compositions comprising the therapeutic polypeptides, as well as methods for using the therapeutic polypeptides, functional equivalents and/or pharmaceutical compositions in the treatment and/or prevention of such medical conditions.
摘要翻译： 本发明涉及从人类早孕尿中发现的β-人绒毛膜促性腺激素（＆bgr--hCG）分离的治疗性多肽，现在合成产生并命名为Maternin。 治疗性多肽及其功能等同物可用于治疗和/或预防各种医疗状况。 治疗性多肽的治疗效果的实例包括抗HIV，抗癌，抗浪费，造血（例如，贫血，辐射介导的骨髓损伤和创伤介导的失血）和抗血管生成作用。 本发明还提供了包含治疗性多肽的药物组合物，以及使用治疗性多肽，功能等同物和/或药物组合物治疗和/或预防这些医学病症的方法。
-
5.发明授权Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin 失效使用人绒毛膜促性腺激素衍生物促进造血的方法
公开(公告)号：US5968513A
公开(公告)日：1999-10-19
申请号：US709924
申请日：1996-09-09
CPC分类号： A61K38/24 , A61K48/00 , Y10S514/885
摘要： The present invention relates to methods of treating or preventing diseases or disorders associated with hematopoietic deficiency by administration of human chorionic gonadotropin, .beta.-human chorionic gonadotropin or a peptide containing a sequence of a portion of .beta.-human chorionic gonadotropin. The invention also relates to methods of treating or preventing diseases or disorders associated with hematopoietic deficiency by administration of hematopoietic cells, the numbers of which have been increased by contacting the cells with human chorionic gonadotropin, .beta.-human chorionic gonadotropin or a peptide containing a sequence of a portion of .beta.-human chorionic gonadotropin. The invention also provides assays for the utility of particular human chorionic gonadotropin preparations in the treatment or prevention of hematopoietic deficiencies or in the increasing of hematopoietic cell numbers in vitro. Pharmaceutical compositions and methods of administration of are also provided.
摘要翻译： 本发明涉及通过施用人绒毛膜促性腺激素，β-人绒毛膜促性腺激素或含有一部分β-人绒毛膜促性腺激素序列的肽来治疗或预防与造血缺陷相关的疾病或病症的方法。 本发明还涉及通过给予造血细胞来治疗或预防与造血缺陷相关的疾病或病症的方法，所述造血细胞的数量通过使细胞与人绒毛膜促性腺激素接触而增加，β-人绒毛膜促性腺激素或含有序列的肽 的一部分β-人绒毛膜促性腺激素。 本发明还提供特异性人绒毛膜促性腺激素制剂用于治疗或预防造血缺陷或增加体外造血细胞数量的测定。 还提供了药物组合物和给药方法。
-
公开(公告)号：US09687469B2
公开(公告)日：2017-06-27
申请号：US14835198
申请日：2015-08-25
申请人： Henry Lowe , Ngeh J. Toyang , Joseph Bryant
发明人： Henry Lowe , Ngeh J. Toyang , Joseph Bryant
IPC分类号： A61K31/353 , C07D311/32
CPC分类号： A61K31/353 , C07D311/32 , C07D311/60
摘要： A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.
-
公开(公告)号：USD742312S1
公开(公告)日：2015-11-03
申请号：US29513788
申请日：2015-01-05
-
公开(公告)号：USD683305S1
公开(公告)日：2013-05-28
申请号：US29430724
申请日：2012-08-29
-
公开(公告)号：USD682777S1
公开(公告)日：2013-05-21
申请号：US29430735
申请日：2012-08-29
-
公开(公告)号：US06699834B1
公开(公告)日：2004-03-02
申请号：US09675362
申请日：2000-09-29
IPC分类号： A01N3718
CPC分类号： C07K14/59
摘要： The present invention relates to peptides of one or more portions of the human chorionic gonadotropin &bgr;-chain as well as methods for treatment of cancer, using human chorionic gonadotropin, employing the &bgr;-chain of human chorionic gonadotropin, peptides containing a sequence of one or more portions of the &bgr;-chain of human chorionic gonadotropin and derivatives and analogues thereof. The invention further relates to fractions of sources and or preparations of human chorionic gonadotropin, such as fractions of human early pregnancy urine, which fractions have anti-cancer activity. The present invention further relates to pharmaceutical compositions for treating cancer.
摘要翻译： 本发明涉及人绒毛膜促性腺激素β链的一个或多个部分的肽以及使用人绒毛膜促性腺激素治疗癌症的方法，其使用人绒毛膜促性腺激素的β-链，含有一个或多个序列的肽 人绒毛膜促性腺激素的β-链的更多部分及其衍生物和类似物。 本发明还涉及人类绒毛膜促性腺激素的来源和/或制剂的分数，例如人类早孕尿的部分，其部分具有抗癌活性。 本发明还涉及用于治疗癌症的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.025 秒)
